Skip to Main Content
CWRU Links

Profiles

David N.  Wald, MD, PhD

David N. Wald, MD, PhD

Director, Hematopoietic Biorepository & Cellular Therapy Core

dnw@case.edu 216.368.5668 (o)

Assistant Professor, Clinical Pathology
Member, Developmental Therapeutics Program and Hematopoietic and Immune Cancer Biology Program

David N. Wald, MD, PhD, is the associate director of the human leukocyte antigen laboratory (HLA) since 2008 and scientific director of hematopoietic biorepository and cellular therapy core since 2010. He is an assistant professor on tenure track at Case Western Reserve University since 2010. He started his work at University Hospitals and Case Western Reserve University in 2005 in a clinical pathology residency. Since then, he has been a postdoctoral fellow and done postdoctoral research in the laboratories of Bryan Roth and William Tse, respectively. Dr. Wald is also a member of the medical advisory board of Lifebanc, a member of the ECOG Leukemia Lab Committee, and a member of the American Cancer Society Drug Development Group Study Section.

Dr. Wald earned a BA in biology from Cornell University in 1997 and studied biology at Cambridge University between 1995 and 1996. He earned a PhD in pathology from Case Western Reserve University in 2003 and an MD from CWRU in 2005. He performed postdoctoral work in oncology at University Hospitals from 2005 to 2008.

View External Profile

View Publications

Dr. Wald's research focuses on cancer model systems and drug development. This includes the identification and development of novel therapeutic strategies for cancer, with a specialty in the treatment of Acute myeloid leukemia (AML) in older patients and colon cancer. Dr. Wald is also researching a natural plant-based compound, securinine, as a treatment for AML. Securinine has potential as a leukemia differentiation-inducing agent because its ability to induce significant growth arrest in cell lines and its activity in impairing the growth of AML tumors in mice.

drug development, cancer, immunology, small molecules, preclinical development, lead optimization chemistry, pharmacologic studies, animal efficacy work, Acute Myeloid Leukemia, leukemia, human leukocyte antigen